Computational Biology Program, Ontario Institute for Cancer Research, Toronto, Ontario, Canada.
Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada.
Cancer Res. 2018 Oct 1;78(19):5527-5537. doi: 10.1158/0008-5472.CAN-18-0362.
Cancer differs significantly between men and women; even after adjusting for known epidemiologic risk factors, the sexes differ in incidence, outcome, and response to therapy. These differences occur in many but not all tumor types, and their origins remain largely unknown. Here, we compare somatic mutation profiles between tumors arising in men and in women. We discovered large differences in mutation density and sex biases in the frequency of mutation of specific genes; these differences may be associated with sex biases in DNA mismatch repair genes or microsatellite instability. Sex-biased genes include well-known drivers of cancer such as β-catenin and Sex influenced biomarkers of patient outcome, where different genes were associated with tumor aggression in each sex. These data call for increased study and consideration of the molecular role of sex in cancer etiology, progression, treatment, and personalized therapy. This study provides a comprehensive catalog of sex differences in somatic alterations, including in cancer driver genes, which influence prognostic biomarkers that predict patient outcome after definitive local therapy. .
癌症在男性和女性之间存在显著差异;即使在调整了已知的流行病学风险因素后,男性和女性在发病率、结局和对治疗的反应方面仍存在差异。这些差异发生在许多(但不是所有)肿瘤类型中,其起源在很大程度上仍然未知。在这里,我们比较了男性和女性肿瘤中的体细胞突变谱。我们发现突变密度和特定基因突变频率的性别偏差存在很大差异;这些差异可能与 DNA 错配修复基因或微卫星不稳定性中的性别偏倚有关。性别偏倚基因包括β-连环蛋白和 AKT1 等众所周知的癌症驱动基因。性别影响患者结局的生物标志物,其中不同的基因与每一种性别中的肿瘤侵袭性相关。这些数据呼吁增加对癌症病因学、进展、治疗和个体化治疗中性别分子作用的研究和考虑。本研究提供了一个全面的癌症驱动基因中体细胞改变性别差异的目录,这些改变影响了预测明确局部治疗后患者结局的预后生物标志物。